Author: Avalon Health Economics LLC

Watch Avalon’s presentation at EuroMedtech in Linz, Austria in May 2014 entitled “Establishing the Value of New Drugs, Devices, & Diagnostics”
July 7, 2014 - 11:15 am, by
Click here to view the presentation
The Evolving Role of the New Generation of Molecular Diagnostics in U.S. Health Markets: Development, Clinical Integration, and Evaluation
July 6, 2014 - 1:35 pm, by
The high cost of adverse events has been estimated to be at least US$177 billion per year in the U.S., and prescription drugs overall have efficacy only approximately 50% of the time, representing a potential waste of approximately $350 billion of the worldwide $700 billion or more drug spending (Miller et al., 2011). The wide...
Nutrition Policy & Food Labeling in the U.S.: A Review & Update
July 6, 2014 - 1:31 pm, by
The Organic and natural food industry has boomed in the last few decades, moving from a small niche market to a $30 billion dollar industry. Across the United States, people are growing more concerned by the possibility that their food choices could negatively affect their health and are responding by buying more products with labels...
Avalon at ISPOR: John Schneider and Cara Scheibling will be attending the annual meeting of the International Society of Pharmacoeconomics and Outcomes Research in Montreal next week, 6/1-6/4
May 31, 2014 - 11:13 am, by
Avalon at ISPOR: John Schneider and Cara Scheibling will be attending the annual meeting of the International Society of Pharmacoeconomics and Outcomes Research in Montreal next week, June 1 through June 4. The title of this year’s meeting is “Examining the Role of Big Data in Health Care Decision Making.” If you’d like to meet,...
Avalon will be attending and presenting at the EuroMedtech conference in Linz, Austria, May 7-8. The topic will be on economic evaluation of devices and diagnostics through the product lifecycle
May 5, 2014 - 11:10 am, by
Avalon will be attending and presenting at the 6th Annual EuroMedtech conference in Linz, Austria, May 7-8. The topic will be on economic evaluation of devices and diagnostics through the product lifecycle. Economic evaluations of new devices and diagnostics should begin early, and should be adjusted and revised throughout the product lifecycle as better data...
New AHE publication: “Epidemiology and Economic Burden of Conjunctivitis: A Managed Care Perspective”
April 1, 2014 - 11:07 am, by
Conjunctivitis is a common condition of the eye that occurs worldwide and affects all ages and social strata, affecting more than 2 percent of the population. It is caused by a variety of bacterial or viral pathogens but may also be caused by allergies, irritants or medications. Most types are self-limiting, but some may progress...
Current Topics in Public Health: Heroin’s Revival
February 6, 2014 - 1:19 pm, by
Heroin has a new face. According to statistics from the National Institute on Drug Abuse, it’s a white male in his 30s and 40s. Surprisingly, heroin use has grown in recent years, sounding alarms among community leaders, public health officials and law enforcement. According to the Substance Abuse and Mental Health Services Administration’s (SAMHSA) National...
The Economics of Ovarian Cancer Diagnosis
February 6, 2014 - 1:09 pm, by
According to estimates from the World Health Organization, 8.3 million people worldwide died from cancer and other neoplasms in 2008—about 14% of all deaths. In the same year, the overall costs of cancer care in the United States amounted to $228.1 billion– $93.2 billion direct medical costs, $18.8 billion in indirect morbidity costs, and $116.1...
Michael J. Lacey, MSc, has joined Avalon Health Economics as a Senior Consultant focusing on Economic Modelling & Value Strategy
February 3, 2014 - 11:03 am, by
Michael J. Lacey, MSc, has joined Avalon Health Economics as a Senior Consultant focusing on Economic Modelling & Value Strategy. He also works as an independent health economics consultant. He has over 15 years industry experience leading new product market access, health economics and pricing strategy development within medical technology firms. He was Senior Director...
Value-Based Purchasing for Hospital Services in the U.S.
January 15, 2014 - 1:05 pm, by
The Center for Medicare and Medicaid Services (CMS) Value-Based Purchasing (VBP) program is an incentive-based repayment plan linked to the quality of care hospitals provide to Medicare patients. With VBP, hospitals are held accountable for both the quality and cost of their services, and must reach specified performance measures to be rewarded. CMS continues to...